1. Dynavax will report Q4 2024 financial results on February 20, 2025. 2. A conference call will follow the earnings release at 4:30 PM ET. 3. Dynavax specializes in vaccines, including HEPLISAV-B for hepatitis B. 4. Company's innovative vaccines may attract investor attention leading up to results.
Upcoming earnings could showcase strong financial growth, similar to past quarters.
Earnings reports can significantly affect stock prices; crucial for investor sentiment.
Immediate market reactions expected post earnings release; past earnings influenced stock price quickly.
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the U.S. financial markets close.
Dynavax will host a conference call and live audio webcast on Thursday, February 20, 2025, at 4:30 p.m. ET/1:30 p.m. PT.
The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.
To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.
Paul Cox example@example.com 510-665-0499
Nicole Arndt example@example.com 510-665-7264
SOURCE Dynavax Technologies